Nancy Y Villa1, Swarna Bais1, Winnie M Chan1, Amy M Meacham1, Elizabeth Wise1, Masmudur M Rahman2, Jan S Moreb1, Emma H Rosenau1, John R Wingard1, Grant McFadden2, Christopher R Cogle3. 1. Division of Hematology & Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA. 2. Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, Florida, USA. 3. Division of Hematology & Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA. Electronic address: christopher.cogle@medicine.ufl.edu.
Abstract
BACKGROUND: Relapsing disease is a major challenge after hematopoietic cell transplantation for hematological malignancies. Myxoma virus (MYXV) is an oncolytic virus that can target and eliminate contaminating cancer cells from auto-transplant grafts. The aims of this study were to examine the impact of MYXV on normal hematopoietic stem and progenitor cells and define the optimal treatment conditions for ex vivo virotherapy. METHODS: Bone marrow (BM) and mobilized peripheral blood stem cells (mPBSCs) from patients with hematologic malignancies were treated with MYXV at various time, temperature and incubation media conditions. Treated BM cells from healthy normal donors were evaluated using flow cytometry for MYXV infection, long-term culture-initiating cell (LTC-IC) assay and colony-forming cell (CFC) assay. RESULTS: MYXV initiated infection in up to 45% of antigen-presenting monocytes, B cells and natural killer cells; however, these infections were uniformly aborted in >95% of all cells. Fresh graft sources showed higher levels of MYXV infection initiation than cryopreserved specimens, but in all cases less than 10% of CD34(+) cells could be infected after ex vivo MYXV treatment. MYXV did not impair LTC-IC colony numbers compared with mock treatment. CFC colony types and numbers were also not impaired by MYXV treatment. MYXV incubation time, temperature or culture media did not significantly change the percentage of infected cells, LTC-IC colony formation or CFC colony formation. CONCLUSIONS: Human hematopoietic cells are non-permissive for MYXV. Human hematopoietic stem and progenitor cells were not infected and thus unaffected by MYXV ex vivo treatment.
BACKGROUND: Relapsing disease is a major challenge after hematopoietic cell transplantation for hematological malignancies. Myxoma virus (MYXV) is an oncolytic virus that can target and eliminate contaminating cancer cells from auto-transplant grafts. The aims of this study were to examine the impact of MYXV on normal hematopoietic stem and progenitor cells and define the optimal treatment conditions for ex vivo virotherapy. METHODS: Bone marrow (BM) and mobilized peripheral blood stem cells (mPBSCs) from patients with hematologic malignancies were treated with MYXV at various time, temperature and incubation media conditions. Treated BM cells from healthy normal donors were evaluated using flow cytometry for MYXV infection, long-term culture-initiating cell (LTC-IC) assay and colony-forming cell (CFC) assay. RESULTS:MYXV initiated infection in up to 45% of antigen-presenting monocytes, B cells and natural killer cells; however, these infections were uniformly aborted in >95% of all cells. Fresh graft sources showed higher levels of MYXV infection initiation than cryopreserved specimens, but in all cases less than 10% of CD34(+) cells could be infected after ex vivo MYXV treatment. MYXV did not impair LTC-IC colony numbers compared with mock treatment. CFC colony types and numbers were also not impaired by MYXV treatment. MYXV incubation time, temperature or culture media did not significantly change the percentage of infected cells, LTC-IC colony formation or CFC colony formation. CONCLUSIONS:Human hematopoietic cells are non-permissive for MYXV. Human hematopoietic stem and progenitor cells were not infected and thus unaffected by MYXV ex vivo treatment.
Authors: Edo Vellenga; Wim van Putten; Gert J Ossenkoppele; Leo F Verdonck; Matthias Theobald; Jan J Cornelissen; Peter C Huijgens; Johan Maertens; Alois Gratwohl; Ron Schaafsma; Urs Schanz; Carlos Graux; Harry C Schouten; Augustin Ferrant; Mario Bargetzi; Martin F Fey; Bob Löwenberg Journal: Blood Date: 2011-09-27 Impact factor: 22.113
Authors: H Yang; C Eaves; M de Lima; M S Lee; R E Champlin; J D McMannis; S N Robinson; T Niu; W K Decker; D Xing; J Ng; S Li; X Yao; A C Eaves; R Jones; B S Andersson; E J Shpall Journal: Bone Marrow Transplant Date: 2006-03 Impact factor: 5.483
Authors: Nancy Y Villa; Clive H Wasserfall; Amy M Meacham; Elizabeth Wise; Winnie Chan; John R Wingard; Grant McFadden; Christopher R Cogle Journal: Blood Date: 2015-04-22 Impact factor: 22.113
Authors: Eric Bartee; Winnie M Chan; Jan S Moreb; Christopher R Cogle; Grant McFadden Journal: Biol Blood Marrow Transplant Date: 2012-04-16 Impact factor: 5.742
Authors: M Kim; G J Madlambayan; M M Rahman; S E Smallwood; A M Meacham; K Hosaka; E W Scott; C R Cogle; G McFadden Journal: Leukemia Date: 2009-10-29 Impact factor: 11.528
Authors: Patrick Kellish; Daniil Shabashvili; Masmudur M Rahman; Akbar Nawab; Maria V Guijarro; Min Zhang; Chunxia Cao; Nissin Moussatche; Theresa Boyle; Scott Antonia; Mary Reinhard; Connor Hartzell; Michael Jantz; Hiren J Mehta; Grant McFadden; Frederic J Kaye; Maria Zajac-Kaye Journal: J Clin Invest Date: 2019-04-29 Impact factor: 14.808
Authors: Stosh Ozog; Nina D Timberlake; Kip Hermann; Olivia Garijo; Kevin G Haworth; Guoli Shi; Christopher M Glinkerman; Lauren E Schefter; Saritha D'Souza; Elizabeth Simpson; Gabriella Sghia-Hughes; Raymond R Carillo; Dale L Boger; Hans-Peter Kiem; Igor Slukvin; Byoung Y Ryu; Brian P Sorrentino; Jennifer E Adair; Scott A Snyder; Alex A Compton; Bruce E Torbett Journal: Blood Date: 2019-10-17 Impact factor: 22.113
Authors: Andrea M Patterson; Sasidhar Vemula; P Artur Plett; Carol H Sampson; Hui Lin Chua; Alexa Fisher; Tong Wu; Rajendran Sellamuthu; Hailin Feng; Barry P Katz; Colleen M DesRosiers; Louis M Pelus; George N Cox; Thomas J MacVittie; Christie M Orschell Journal: Radiat Res Date: 2022-09-01 Impact factor: 3.372
Authors: Xianfang Wu; Viet Loan Dao Thi; Yumin Huang; Eva Billerbeck; Debjani Saha; Hans-Heinrich Hoffmann; Yaomei Wang; Luis A Vale Silva; Stephanie Sarbanes; Tony Sun; Linda Andrus; Yingpu Yu; Corrine Quirk; Melody Li; Margaret R MacDonald; William M Schneider; Xiuli An; Brad R Rosenberg; Charles M Rice Journal: Cell Date: 2017-12-14 Impact factor: 41.582
Authors: Cameron L Lilly; Nancy Y Villa; Ana Lemos de Matos; Haider M Ali; Jess-Karan S Dhillon; Tom Hofland; Masmudur M Rahman; Winnie Chan; Bjarne Bogen; Christopher Cogle; Grant McFadden Journal: Mol Ther Oncolytics Date: 2016-12-14 Impact factor: 7.200